Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Horizon Introduces Quantitative Multiplex Genomic Reference Standards

Published: Friday, March 08, 2013
Last Updated: Thursday, March 07, 2013
Bookmark and Share
Increasing the precision and utility of molecular assays for cancer genotype screening.

Horizon Diagnostics (HDx) has announced that it has launched its first Quantitative Multiplex DNA Reference Standard.

This standard is the first of its kind and is intended for researchers assessing multiple biomarkers in a single assay, using platforms such as next generation sequencing (NGS).

As multiplex assays and large tumor profiling projects become more common, standardization will be essential to enable confidence in experimental results.

To date, a significant challenge has been access to reliable, renewable external reference standards.

HDx’s novel Quantitative Multiplex DNA Reference Standard directly addresses this need by enabling researchers to quantify a range of detection thresholds for 11 cancer relevant mutations.

This is accomplished across complex samples in a single assay in the form of renewable material originating from precisely engineered cell lines.

The reference standard is available as genomic DNA and will be available in a matched formalin fixed paraffin embedded (FFPE) format in Q2, 2013.

The mutations were engineered into endogenous loci using Horizon’s proprietary genome editing platform, GENESIS™.

HDx has verified the Quantitative Multiplex DNA Reference Standard using digital PCR and the product has undergone extensive validation by external partners using NGS platforms such as Ion Torrent™.

Further validation is planned using MiSeq™ and Sequenom Mass Array™ Platforms.

“NGS workflows can be complex, typically involving extraction and amplification steps prior to sequencing and bioinformatic analysis. This gives scope for significant variability, which reduces confidence in the data generated, with the potential for some biomarkers being missed altogether,” Horizon’s VP of Products, Dr Paul Morrill, commented.

Dr Morrill continued, “To date, HDx has been successful in enabling laboratories with reliable and renewable singleplex reference standards. With the development and launch of this new Multiplex Standard, HDx is better able to support customers as they address the complexity of tumor genetics, driving towards better understanding of disease and ultimately better patient care.”

HDx will be actively expanding its list of Multiplex Reference Standards over the coming months.

The company is also open to working with clients seeking to develop custom standards with specific customer-defined genotypes and allelic frequencies.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Horizon, Sophia Genetics Partner to Improve NGS Testing for Cancer
Partnership combines Horizon’s HDx™ Reference Standards with Sophia Genetics’ artificial intelligence.
Friday, November 18, 2016
Horizon Discovery Enters Chinese Clinical Diagnostics Market
Three leading Chinese diagnostic kit manufacturers have initiated clinical trials using Horizon HDx™ Reference Standards.
Thursday, November 17, 2016
Horizon Discovery, CareDx Signs OEM Agreement
Under the agreement, company will supply cell-free DNA-based molecular reference standards for inclusion in CareDx’s cfDNA testing workflows for the monitoring of transplanted organ rejection.
Thursday, November 10, 2016
Horizon Discovery Announces Two Fresh Licensing Agreements
Horizon Discovery licenses biomanufacturing cell lines to Centre for Process Innovation (CPI) and National Institute for Bioprocessing Research and Training (NIBRT).
Tuesday, September 13, 2016
Horizon, Fulcrum Launch Collaboration
Horizon Discovery and Fulcrum Therapeutics form collaboration for novel CRISPR-based target discovery in genetic diseases.
Tuesday, September 06, 2016
Horizon, Ventana Sign Co-Development Agreement
The agreement covers the development, manufacture and commercialisation of cell line derivative materials for use as IHC Reference Standards.
Friday, September 02, 2016
Wistar, Horizon Ink Exclusive License Deal
The Wistar Institute has granted Horizon Discovery an exclusive license to 153 of its Melanoma Patient-Derived Xenograft models.
Thursday, July 21, 2016
Horizon, Centauri Therapeutics Launch Collaboration
Joint venture creates a differentiated new player in the rapidly growing immuno-oncology market, currently valued at £25 billion.
Thursday, March 03, 2016
Horizon Signs Three Diagnostic Agreements Worth an Initial $3.3 Million
Agreements with three global companies for test development and validation.
Thursday, November 26, 2015
Horizon Launches New E-commerce Platform and Expands UK Headquarters
Key investment includes an integrated web-shop and Enterprise Resource Planning system to support further scale and revenue growth.
Thursday, October 29, 2015
Horizon, Swift Partner on Genomic Reference Standards
Standards to be used to support validation, consistency and accuracy of the panel.
Wednesday, October 28, 2015
Horizon In-licenses Oncology Programme from Servier
License programme with milestone payments of up to £50 million plus royalties on product sales.
Thursday, October 08, 2015
Horizon Enters Licensing Agreement with LakePharma
The terms of the license cover commercial use of a genetically-engineered Chinese Hamster Ovary (CHO) cell line, developed by Horizon and adapted to manufacturing conditions by LakePharma.
Thursday, September 17, 2015
Horizon Enters Bioproduction Cell Line Licensing Agreement with LakePharma, Inc.
LakePharma to take a full commercial license for GS null CHO K1 cell line from Horizon for improved efficiency in biopharmaceutical manufacturing.
Wednesday, September 16, 2015
Horizon, Abcam Sign License and Supply Agreement
Horizon Discovery Group plc and Abcam plc have announced the formation of a license and supply agreement between the two companies.
Wednesday, September 09, 2015
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Automated Low Volume Dispensing Trends
Gain a better understanding of the current and future market requirements for fully automated LVD systems.
Forensic 3D Documentation of Skin Injuries
In this study, the validity of using photogrammetry for documenting injuries in a pathological context was demonstrated.
3-D Printed Dog’s Nose Improves Vapor Detection
By mimicking how dogs get their whiffs, a team of government and university researchers have demonstrated that “active sniffing” can improve by more than 10 times the performance of current technologies that rely on continuous suction to detect trace amounts of explosives and other contraband.
New Markers for Forensic Body-fluid Identification
University of Bonn researchers have successfully identified specific Micro-RNA signatures to help forensically identify body fluids.
Genetics Control Regenerative Properties Of Stem Cells
Researchers define how genetic factors control regenerative properties of blood-forming stem cells.
Major Neuroscience Initiative Launched
Tianqiao and Chrissy Chen Institute invest $115 million to further expand neuroscience research, while Caltech construct $200 million biosciences complex.
Making It Personal
Cancer vaccine linked to increased immune response against leukemia cells.
Unique Visual Stimulation May Be New Treatment for Alzheimer’s
Noninvasive technique reduces beta amyloid plaques in mouse models of Alzheimer’s disease.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!